Conventional therapy and approach to management

S Vincent Rajkumar, Robert A. Kyle

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The treatment of multiple myeloma (MM) has undergone major changes in the last decade. There is now an array of therapeutic options, including autologous stem-cell transplantation, non-myeloablative (mini) allogeneic transplantation, and new drugs such as thalidomide and bortezomib. There is also an awareness that there are subsets of patients with MM who have not gained much from the recent advances, including patients with certain adverse prognostic factors (high-risk MM). In this article, we outline our approach to the diagnosis, risk stratification and treatment of MM with a focus on conventional therapy. We incorporate a risk-based strategy for the treatment of MM that also takes into account the eligibility of the patient to undergo stem-cell transplantation. We also outline the role and current indications for the use of new active agents in this disease.

Original languageEnglish (US)
Pages (from-to)585-601
Number of pages17
JournalBest Practice and Research: Clinical Haematology
Volume18
Issue number4 SPEC. ISS.
DOIs
StatePublished - Dec 2005

Fingerprint

Multiple Myeloma
Stem cells
Stem Cell Transplantation
Thalidomide
Therapeutics
Homologous Transplantation
Pharmaceutical Preparations

Keywords

  • Bortezomib
  • Chemotherapy
  • Corticosteroids
  • Melphalan
  • Myeloma
  • Thalidomide
  • Transplantation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Conventional therapy and approach to management. / Rajkumar, S Vincent; Kyle, Robert A.

In: Best Practice and Research: Clinical Haematology, Vol. 18, No. 4 SPEC. ISS., 12.2005, p. 585-601.

Research output: Contribution to journalArticle

@article{88a464b6ce244eb59e22ae7bdc894d51,
title = "Conventional therapy and approach to management",
abstract = "The treatment of multiple myeloma (MM) has undergone major changes in the last decade. There is now an array of therapeutic options, including autologous stem-cell transplantation, non-myeloablative (mini) allogeneic transplantation, and new drugs such as thalidomide and bortezomib. There is also an awareness that there are subsets of patients with MM who have not gained much from the recent advances, including patients with certain adverse prognostic factors (high-risk MM). In this article, we outline our approach to the diagnosis, risk stratification and treatment of MM with a focus on conventional therapy. We incorporate a risk-based strategy for the treatment of MM that also takes into account the eligibility of the patient to undergo stem-cell transplantation. We also outline the role and current indications for the use of new active agents in this disease.",
keywords = "Bortezomib, Chemotherapy, Corticosteroids, Melphalan, Myeloma, Thalidomide, Transplantation",
author = "Rajkumar, {S Vincent} and Kyle, {Robert A.}",
year = "2005",
month = "12",
doi = "10.1016/j.beha.2005.01.011",
language = "English (US)",
volume = "18",
pages = "585--601",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "4 SPEC. ISS.",

}

TY - JOUR

T1 - Conventional therapy and approach to management

AU - Rajkumar, S Vincent

AU - Kyle, Robert A.

PY - 2005/12

Y1 - 2005/12

N2 - The treatment of multiple myeloma (MM) has undergone major changes in the last decade. There is now an array of therapeutic options, including autologous stem-cell transplantation, non-myeloablative (mini) allogeneic transplantation, and new drugs such as thalidomide and bortezomib. There is also an awareness that there are subsets of patients with MM who have not gained much from the recent advances, including patients with certain adverse prognostic factors (high-risk MM). In this article, we outline our approach to the diagnosis, risk stratification and treatment of MM with a focus on conventional therapy. We incorporate a risk-based strategy for the treatment of MM that also takes into account the eligibility of the patient to undergo stem-cell transplantation. We also outline the role and current indications for the use of new active agents in this disease.

AB - The treatment of multiple myeloma (MM) has undergone major changes in the last decade. There is now an array of therapeutic options, including autologous stem-cell transplantation, non-myeloablative (mini) allogeneic transplantation, and new drugs such as thalidomide and bortezomib. There is also an awareness that there are subsets of patients with MM who have not gained much from the recent advances, including patients with certain adverse prognostic factors (high-risk MM). In this article, we outline our approach to the diagnosis, risk stratification and treatment of MM with a focus on conventional therapy. We incorporate a risk-based strategy for the treatment of MM that also takes into account the eligibility of the patient to undergo stem-cell transplantation. We also outline the role and current indications for the use of new active agents in this disease.

KW - Bortezomib

KW - Chemotherapy

KW - Corticosteroids

KW - Melphalan

KW - Myeloma

KW - Thalidomide

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=22144460170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144460170&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2005.01.011

DO - 10.1016/j.beha.2005.01.011

M3 - Article

VL - 18

SP - 585

EP - 601

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 4 SPEC. ISS.

ER -